Matters surrounding PSMA therapy that require clarification in future research:
 

The need to administer amino acids or alternative forms of intravenous hydration (such as saline) to protect the kidneys during PSMA therapy.

Whether Lu-177-PSMA therapy can also be applied in an earlier stage of disease than metastatic castration-resistant prostate cancer.

The effects of combination therapy with androgen blockade.

The effects of combination therapy with chemotherapy or radiation.

Adding steroids to therapy and investigating risks and benefits.

The minimum required number of cycles of PSMA therapy and decisions about continuation of therapy.

Optimizing and individualizing the amount of radioactivity administered.

Minimize and treat salivary gland toxicity.

Funding the research.